Table 2.
Correlation between the decline in CD4+ proportions and the increase in the symptoms score
| CD4+ (%) | Months |
Score | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 0–5 | 6 | 7 | 8 | 9 | 11 | 15 | |||
| Saline | |||||||||
| 1 | 45.74 | – | MW | MW | MW | – | MW | O,MW,SL | |
| 2 | 2 | 2 | 0 | 2 | 1,2,1 | 12 | |||
| 2 | 39.95 | – | MW | MW | MW | – | O,MW | O,SL | |
| 2 | 2 | 2 | 0 | 1,2 | 1,1 | 11 | |||
| 3 | 50.42 | – | O, MW | O, MW | O, MW | – | SW,O | O,SW,SL | |
| 1,2 | 1,2 | 1,2 | 0 | 3,1 | 1,3,1 | 18 | |||
| 7 | 7.71 | – | O,MW | O,MW | O,MW | O,MW | SW,O | SW,O | |
| 1,2 | 1,2 | 1,2 | 1,2 | 3,1 | 3,1 | 20 | |||
| 8 | 16.32 | – | O,MW | O,MW | O,MW | MW | SW,O | A, S,O, SW,LL | |
| 1,2 | 1,2 | 1,2 | 2 | 3,1 | 1,1,1,3,3 | 24 | |||
| 9 | 42.91 | – | O,MW | O,MW | O,MW | – | MW,O | MW,O,SL | |
| 1,2 | 1,2 | 1,2 | 0 | 2,1 | 2,1,1, | 16 | |||
| 10 | 27.65 | – | O,MW | O,MW | O,MW | O | SW,O | O,SW,ML | |
| 1,2 | 1,2 | 1,2 | 1 | 3,1 | 1,3,2 | 20 | |||
| 15 | 6.5 | – | O,MW | O,MW | O,MW | O | MW,O, OE | O,ML | |
| 1,2 | 1,2 | 1,2 | 1 | 2,1,1 | 1,2 | 17 | |||
| 17 | 50.45 | – | O,A,S | O,A,SL | O,A,SL | O | MW,O | MW,O,SL | |
| 1,1,1 | 1,1,1 | 1,1,1 | 1 | 2,1 | 2,1,1 | 17 | |||
| 20 | 39.29 | – | O,MW | O,MW | O,MW | O | MW,O | O,MW,LL | |
| 1,2 | 1,2 | 1,2 | 1 | 2,1 | 1,2,3 | 19 | |||
| 21 | 50.61 | – | O,MW | O,MW | O,MW | MW | SW,O | O,SW,ML | |
| 1,2 | 1,2 | 1,2 | 1 | 3,1 | 1,3,2 | 20 | |||
| 25 | 8.04 | – | O,MW | O,MW | O,MW | – | SW,O | SW,O,LL | |
| 1,2 | 1,2 | 1,2 | 0 | 3,1 | 3,1,3 | 20 | |||
| Total scores | 34 | 34 | 34 | 10 | 42 | 60 | 214 | ||
| CI 95% | 17.83 (19.96–15.69) | ||||||||
| Vaccinees | |||||||||
| 4 | 42.07 | – | O,MW | O,MW | O,MW | MW | O | O,SL | |
| 1,2 | 1,2 | 1,2 | 2 | 1 | 1,1 | 14 | |||
| 5 | 37.45 | – | O,MW | O,MW | O,MW | – | O | O,MW,SL | |
| 1,2 | 1,2 | 1,2 | 0 | 1 | 1,2,1 | 14 | |||
| 6 | 43.17 | – | O,MW | O,MW | O,MW | – | O, MW | SW, SL | |
| 1,2 | 1,2 | 1,2 | 0 | 1,2 | 3,1 | 16 | |||
| 11 | 52.09 | – | O,MW | O,MW | O,MW | O,MW | SW,O | SW,O,ML | |
| 1,2 | 1,2 | 1,2 | 1,2 | 3,1 | 3,1,2 | 22 | |||
| 12 | 43.87 | – | O,MW | O,MW | O,MW | O,MW | SW,O | O,MW, SL | |
| 1,2, | 1,2 | 1,2 | 1,2 | 3,1 | 1,2,1 | 20 | |||
| 13 | 46.05 | – | MW | MW | MW | O,MW | O, MW | O,LL | |
| 2 | 2 | 2 | 1,2 | 1,2 | 1,3 | 16 | |||
| 14 | 46.66 | – | MW | MW | MW | – | O,MW | O,SL | |
| 2 | 2 | 2 | 0 | 1,2 | 1,1 | 11 | |||
| 16 | 48.86 | – | O,MW | O,MW | O,MW | O,A | O | O,MW,SL | |
| 1,2 | 1,2 | 1,2 | 1,1 | 1 | 1,2,1 | 16 | |||
| 19 | 53.61 | – | MW | MW | MW | O | O,MW | MW,O,SL | |
| 2 | 2 | 2 | 1 | 1,2 | 2,1,1 | 14 | |||
| 22 | 45.05 | – | O,MW | O,MW | O,MW | – | O | MW,SL,O | |
| 1,2 | 1,2 | 1,2 | 0 | 1 | 2,1,1, | 14 | |||
| 23 | 49.77 | – | O,MW | O,MW | O,MW | O | O,MW | O,MW,ML | |
| 1,2 | 1,2 | 1,2 | 1 | 1,2 | 1,2,2 | 18 | |||
| 24 | 53.84 | – | O,MW | O,MW | O,MW | – | O,MW | O,SL | |
| 1,2 | 1,2 | 1,2 | 0 | 1,2 | 1,1 | 14 | |||
| Total scores | 33 | 33 | 33 | 15 | 30 | 45 | 189 | ||
| CI (95%) | 15.75 (17.53–13.97) | ||||||||
Animals were clinically evaluated monthly for: alopecia (A); onycogryphosis (O); skin lesions (S), oedema (OE), popliteal and cervical lymph node enlargement and loss of weight.
Three levels of lymph node enlargement were discriminated: 0 for no detection, 1 for small (SL; up to 1 cm); 2 for medium (ML; 1–1.5 cm) and 3 for large lymph nodes (LL; ≥2 cm). Loss of weight was also classified as 2 for mild weight loss (MW) when ranging from 0–2 kg, and 3 for severe weight loss (SW) when ranging from 2–5 kg. Detection of alopecia; onycogryphosis or skin lesions or oedema were considered of value = 1.